RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval

RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) RINVOQ is the first and only JAK inhibitor approved for both active ankylosing spondylitis (AS) and nr-axSpA1-3 In a clinical study, RINVOQ delivered…